High-Dose Caspofungin as a Component of Combination Antifungal Therapy in 91 Patients With Neoplastic Diseases and Hematopoietic Stem Cell Transplantation
Restricted accessResearch articleFirst published online April, 2015
High-Dose Caspofungin as a Component of Combination Antifungal Therapy in 91 Patients With Neoplastic Diseases and Hematopoietic Stem Cell Transplantation
The antifungal activity of echinocandins is concentration dependent. Previously, we demonstrated that high-dose caspofungin (HD-CSP; 100 mg daily) was well tolerated in 34 immunosuppressed patients with cancer and may have favorably influenced outcomes. We retrospectively assessed all 91 patients in whom HD-CSP was given for the treatment of invasive fungal disease (IFD). The median number of doses was 18.5 ± 21.5, and in 8 (9%) patients more than 40 doses were given. Most (62%) of the patients had leukemia. A total of 45 (49%) patients had undergone stem cell transplantation; 80% received allogeneic grafts and 47% had graft-versus-host disease. High-dose corticosteroids were given during antifungal therapy in 26 (29%) patients. In all, 8 (9%) patients had new elevation in serum bilirubin during HD-CSP therapy; normalization occurred after voriconazole and HD-CSP were discontinued in 4 patients each. No other short-term or delayed adverse events were observed. In all, 40 (44%) patients died of IFD. High-dose corticosteroids during HD-CSP (odds ratio [OR] 8, 95% confidence interval [CI] 2.1-30.4; P < .002) and starting HD-CSP in the critical care unit (OR 67.5, 95% CI 5.25-868.9; P < .001) were associated with death from fungal disease. Prolonged HD-CSP therapy was well tolerated. Drug-induced hyperbilirubinemia may pose a potential limitation for continued HD-CSP use in highly susceptible patients with hematologic neoplasms and stem cell transplantation.
EggerSSMeierSLeuC. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010;45(7):1197–1203.
2.
WiederholdNPKontoyiannisDPChiJ. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190(8):1464–1471.
3.
SafdarARodriguezGRolstonKV. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(3):157–164.
4.
GrollAHGullickBMPetraitieneR. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother. 2001;45(2):596–600.
5.
SandhuPXuXBondiskeyPJ. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother. 2004;48(4):1272–1280.
6.
StoneJAHollandSDWickershamPJ. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002;46(3):739–745.
7.
BettsRFNucciMTalwarD. Caspofungin high-dose study group. a multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48(12):1676–1684.
8.
LaroneD. Medically Important Fungi: a Guide to Identification. Washington, DC: ASM Press; 1995.
9.
De PauwBWalshTJDonnellyJP. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–1821.
10.
SafdarASinghalSMehtaJ. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993–2001). Cancer. 2004;100(11):2456–2461.
11.
KnausWADraperEAWagnerDP. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.
12.
HerbrechtRMaertensJBailaL. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. Bone Marrow Transplant. 2010;45(7):1227–1233.
13.
KontoyiannisDPHachemRLewisRE. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299.
14.
RaadIIHannaHABoktourM. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008;22(3):496–503.
15.
StevensDAWhiteTCPerlinDS. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis. 2005;51(3):173–178.
16.
FortwendelJRJuvvadiPRPerfectBZ. Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother. 2010;54(4):1555–1563.
17.
LamarisGALewisREChamilosG. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008;198(2):186–192.
18.
WheelerRTFinkGR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2006;2(4):e35.
19.
van de SandeWWvan VianenWten KateMT. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2008;52(4):1345–1350.
20.
HaoBChengSClancyCJ. Caspofungin kills Candida albicans by causing both cellular apoptosis and necrosis. Antimicrob Agents Chemother. 2013;57(1):326–332.
21.
OlsonJAGeorgeAConstableD. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother. 2010;54(9):3884–3894.
22.
MacCallumDMWhyteJAOddsFC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother. 2005;49(9):3697–3701.
23.
GrollAHSillingGYoungC. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010;54(10):4143–4149.
CaillotDThiébautAHerbrechtR. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746.
26.
SafdarARodriguezGZunigaJ. Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol. 2013;129(1):26–34.
27.
SafdarARodriguezGHLichtigerB. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006;106(12):2664–2671.
28.
SafdarAHannaHABoktourM. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004;101(12):2859–2865.
29.
SafdarA. Immunomodulation therapy for invasive aspergillosis: discussion on myeloid growth factors, recombinant cytokines, and antifungal drug immune modulation. Curr Fungal Infect Rep. 2010;4(1):1–7.
30.
SafdarA. Immunotherapy for invasive mold disease in severely immunosuppressed patients. Clin Infect Dis. 2013;57(1):94–100.
